Ephrin Receptor

The Eph receptor tyrosine kinase (RTK) family comprises the largest group of surface receptors and are categorized into EphA or EphB subclasses based on sequence homology and preferential binding to their ephrin-A and ephrin-B ligands, respectively.

In humans, nine EphA (EphA1-8,10) and five EphB (EphB1-4,6) receptors are expressed, along with five ephrin-A and three ephrin-B ligands. Unlike most RTKs, Eph receptors interact with ligands that are often membrane-bound, allowing both “forward signaling” in the receptor-bound cell and “reverse signaling” in the ephrin-bound cell. In addition to “forward signaling,” Eph receptors can signal in the absence of ligand binding and kinase activation through cross-talk with other RTKs, such as HER2.

Eph receptor tyrosine kinases and their ligands, the ephrins, play key roles in the regulation of migration and cell adhesion during development, thereby influencing cell fate, morphogenesis and organogenesis. By now, many Eph receptors and ephrins have also been found to play important roles in the progression of cancer. Therefore, the Eph/ephrin system is considered a promising therapeutic target.

Ephrin Receptor Inhibitors, Agonists & Antagonists

123C4

Cat. No.: HY-P0177

123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase **EPHA4**, with a K_i value of 0.65 μM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ALW-II-41-27

(Eph receptor tyrosine kinase inhibitor)

Cat. No.: HY-18007

ALW-II-41-27 is a **Eph** family tyrosine kinase inhibitor with an IC_{50} of 11 nM for Eph2.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Eph inhibitor 2

Cat. No.: HY-131005

Eph inhibitor 2 (Example 35) is a **Eph** family tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JI-101

Cat. No.: HY-16265

JI-101 is an orally available multi-kinase inhibitor of **VEGFR2**, **PDGFRβ** and **EphB4** with potent anti-cancer activity.



Purity: 99.43%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

KYL peptide

Cat. No.: HY-P2264

KYL peptide, an antagonistic peptide, selectively targets **EphA4 receptor**. KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride is a potent and orally bioavailable **Raf** inhibitor, with IC_{50}s of 2.1, 4.2, and 2.5 nM for ^{V600E}**ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (IC_{50}=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-BHG712

(BHG712)

Cat. No.: HY-13258A

NVP-BHG712 is an oral active **EphB4 kinase autophosphorylation** inhibitor, with IC_{50} values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BHG712 isomer

Cat. No.: HY-13258

NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tesevatinib

(XL-647; EXEL-7647; KD-019)

Cat. No.: HY-13314

Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits **EGFR**, **ErbB2**, **KDR**, **Flt4** and **EphB4** kinase with IC_{50}s of 0.3, 16, 1.5, 8.7, and 1.4 nM.



Purity: 99.21%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

UniPR129

Cat. No.: HY-123607

UniPR129 is a potent **Eph/ephrin** antagonist. UniPR129 has the potential for the research of cancer disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

UniPR505

Cat. No.: HY-146375

UniPR505 (Compound 14) is an **EphA2** antagonist with an IC_{50} of 0.95 μM. UniPR505 displays anti-angiogenic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg